Evidence map›Paper›PMID 32012866›Full record

ArticleCancers2020

Genomic Landscape of Young-Onset Bladder Cancer and Its Prognostic Implications on Adult Bladder Cancer.

Sun-Wha Im, Chang Ohk Sung, Kun Suk Kim, Nam Hoon Cho, Young Min Kim, Ghee Young Kwon, Kyung Chul Moon, Song-Yi Choi, Jae Sung Lim, Yeong Jin Choi and 13 more

Abstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sun-Wha ImGenomic Medicine Institute, Medical Research Center, Seoul National University, Seoul 03080, Korea.
Chang Ohk SungDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Kun Suk KimDepartment of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Nam Hoon ChoDepartment of Pathology, Yonsei Medical University College of Medicine, Seoul 03722, Korea.
Young Min KimDepartment of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan 44033, Korea.
Ghee Young KwonDepartment of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Kyung Chul MoonDepartment of Pathology, Seoul National University College of Medicine, Seoul 03080, Korea.
Song-Yi ChoiDepartment of Pathology, Chungnam National University College of Medicine, Daejeon 35015, Korea.
Jae Sung LimDepartment of Urology, Chungnam National University College of Medicine, Daejeon 35015, Korea.
Yeong Jin ChoiDepartment of Hospital Pathology, The Catholic University of Korea, Seoul 06591, Korea.
Soo Jin JungDepartment of Pathology, Inje University Busan Paik Hospital, Busan, Seoul 47392, Korea.
So Dug LimDepartment of Pathology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Sung Hyun PaickDepartment of Urology, School of Medicine, Konkuk University, Seoul 05029, Korea.
Ok-Jun LeeDepartment of Pathology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju 28644, Korea.
Ho Won KangDepartment of Urology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju 28644, Korea.
Seo Hee RhaDepartment of Pathology, College of Medicine, Dong-A University, Busan 49201, Korea.
Hee Sang HwangDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.
Ja-Min ParkAsan Institute of Life Science, Asan Medical Center, Seoul 05505, Korea.
Sun Young YoonAsan Institute of Life Science, Asan Medical Center, Seoul 05505, Korea.
Jeesoo ChaeDepartment of Biomedical Science, Seoul National University Graduate School, Seoul 03080, Korea.
Jaeyong ChoiDepartment of Biomedical Science, Seoul National University Graduate School, Seoul 03080, Korea.
Jong-Il KimGenomic Medicine Institute, Medical Research Center, Seoul National University, Seoul 03080, Korea.
Yong Mee ChoDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, Korea.

Funding

Korea Health Industry Development Institute HI13C2148National Research Foundation of Korea 2019R1A2C1088246
6 · The paper itself

Abstract

Due to the rare occurrence of young-onset bladder cancer (YBC), its genomic characteristics remain largely unknown. Twenty-nine biopsy-proven YBC cases were collected using a nation-wide search for bladder cancer diagnosed at 20 years or younger. Whole exome sequencing and RNA sequencing were carried out in 21 and 11 cases, respectively, and compared with those of adult bladder cancer (ABC) cases obtained from public databases. Almost all YBCs were low grade, non-invasive papillary tumors. YBC had a low mutation burden and less complex copy number alterations. All cases harbored putative driver mutations. Mutations were most commonly found in HRAS (10 cases), with a preference for exon 5. FGFR3 gene fusions were noted with various partner genes (7 cases). The alterations on HRAS and FGFR3 occurred in a mutually exclusive manner. Others included KRAS mutations (2 cases), chromosomes 4p and 10q arm-level deletions (1 case), and ERCC2 mutation (1 case). There were no point mutations in TP53 and FGFR3. The gene expression profiles of YBC were similar to those of the ABC group with good prognosis. None of the YBCs and ABCs with YBC-like mutations showed progression to muscle-invasive tumors. Our results suggest that bladder cancer with YBC-like mutations represents an indolent bladder tumor, regardless of age.

Indexed as

FGFR3HRASnext generation sequencingprognosisyoung-onset bladder cancer

Identifiers

PMID32012866
PMCPMC7073191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.